{"name":"Janssen Scientific Affairs, LLC","slug":"janssen-scientific-affairs-llc","ticker":"","exchange":"","domain":"janssenscientificaffairsllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Placebo for Ustekinumab","genericName":"Placebo for Ustekinumab","slug":"placebo-for-ustekinumab","indication":"Control arm in Phase 3 clinical trial of ustekinumab (active comparator)","status":"phase_3"},{"name":"INI Based Regimen","genericName":"INI Based Regimen","slug":"ini-based-regimen","indication":"Other","status":"marketed"},{"name":"Nucynta ER","genericName":"Nucynta ER","slug":"nucynta-er","indication":"Other","status":"marketed"},{"name":"Placebo for Adalimumab","genericName":"Placebo for Adalimumab","slug":"placebo-for-adalimumab","indication":"Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor)","status":"phase_3"},{"name":"Tramadol HCl, 50 mg","genericName":"Tramadol HCl, 50 mg","slug":"tramadol-hcl-50-mg","indication":"Other","status":"phase_1"},{"name":"haloperidole","genericName":"haloperidole","slug":"haloperidole","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Ustekinumab (90 mg)","genericName":"Ustekinumab (90 mg)","slug":"ustekinumab-90-mg","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Adalimumab (40 mg)","genericName":"Adalimumab (40 mg)","slug":"adalimumab-40-mg","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"aspirin (ASA)","genericName":"aspirin (ASA)","slug":"aspirin-asa","indication":"Acute myocardial infarction","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Darunavir/Cobicistat (FDC)","genericName":"Darunavir/Cobicistat (FDC)","slug":"darunavir-cobicistat-fdc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"TAF/FTC FDC","genericName":"TAF/FTC FDC","slug":"taf-ftc-fdc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Cilta-cel OOS Therapy","genericName":"Cilta-cel OOS Therapy","slug":"cilta-cel-oos-therapy","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Placebo for Ustekinumab","genericName":"Placebo for Ustekinumab","slug":"placebo-for-ustekinumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial of ustekinumab (active comparator)"],"catalyst":""},{"name":"Darunavir/Cobicistat (FDC)","genericName":"Darunavir/Cobicistat (FDC)","slug":"darunavir-cobicistat-fdc","phase":"marketed","mechanism":"Darunavir is a protease inhibitor that blocks HIV protease to prevent viral replication, while cobicistat is a boosting agent that inhibits CYP3A4 to increase darunavir levels.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in combination with other antiretroviral agents"],"catalyst":""},{"name":"INI Based Regimen","genericName":"INI Based Regimen","slug":"ini-based-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ustekinumab (90 mg)","genericName":"Ustekinumab (90 mg)","slug":"ustekinumab-90-mg","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Moderate to severe Crohn's disease"],"catalyst":""},{"name":"Adalimumab (40 mg)","genericName":"Adalimumab (40 mg)","slug":"adalimumab-40-mg","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Cilta-cel OOS Therapy","genericName":"Cilta-cel OOS Therapy","slug":"cilta-cel-oos-therapy","phase":"phase_2","mechanism":"Chimeric antigen receptor T-cell therapy","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Nucynta ER","genericName":"Nucynta ER","slug":"nucynta-er","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo for Adalimumab","genericName":"Placebo for Adalimumab","slug":"placebo-for-adalimumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor)"],"catalyst":""},{"name":"TAF/FTC FDC","genericName":"TAF/FTC FDC","slug":"taf-ftc-fdc","phase":"marketed","mechanism":"TAF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"],"catalyst":""},{"name":"Tramadol HCl, 50 mg","genericName":"Tramadol HCl, 50 mg","slug":"tramadol-hcl-50-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"aspirin (ASA)","genericName":"aspirin (ASA)","slug":"aspirin-asa","phase":"marketed","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.","indications":["Acute myocardial infarction","Secondary prevention of myocardial infarction and stroke","Unstable angina","Transient ischemic attack (TIA) prevention","Mild to moderate pain and fever"],"catalyst":""},{"name":"haloperidole","genericName":"haloperidole","slug":"haloperidole","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPWFlQZ2dLeXBXbi1UbFUxaEpSQy0zVy1mWlJCTkFrREtwOUpVZlVqdnJmd1ZfUENyMWs1aDVibmwzdFpBQ3NOdjNqMnk4MzVVUmNGT0hDRHd2cE41cUY5c2plNE5JbzZYRzFLbGdZS1MtNVdfZkRrc2x3NVZmLTJVZ1p5c1lsVGlwblFKd201b21xcEV1NF9DSW4yZXNoeXFlcTlsN1VsbzdKdWJMbXY4S0VYdUhnRlJpdDBDUzJB?oc=5","date":"2025-10-24","type":"pipeline","source":"The Johns Hopkins News-Letter","summary":"Lessons from the opioid crisis: How marketing shaped military pain treatment - The Johns Hopkins News-Letter","headline":"Lessons from the opioid crisis: How marketing shaped military pain treatment - The Johns Hopkins News","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-09","type":"pipeline","source":"prnewswire.com","summary":"Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venere","headline":"Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFA4Y1dSZWZ3WThKamtBSzlEbHhFVkpGWnVBNlhzeXVKcGNtVUo2WEtkTDFsZDV6dmxNV1NLLTZ0VDEwWm10NDBaRk5JUWFDQU16bnNkdTlqbno1VGdpSVVwMU1uTTRWUnBGVGJv?oc=5","date":"2023-09-10","type":"trial","source":"Wiley Online Library","summary":"Impact of the COVID-19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension-specific therapy in the United States of America: An observational study ","headline":"Impact of the COVID-19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypert","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQTGdFS1hLNGlMZW1kUEZvaGU2dnBlZGdGa0x6V0JEUDdzdnVwaGpxZ09OUEJGMlJMdTdIMmJWenhHVE5vU0Ftd2pYdWFReWszQm9sQlhLX3p1LXg0SHZ5bnpGM0sxbGpLSl9ERXNCNnpiR01IcDhXWE1fRzBmV1hGeDEzM1kyMjJRdWNRN1dDd0VUUVFaYjZ4N29YTTZPZURuNkFDdVE0ZGNsbDBlLWFpS0pHZVR0QQ?oc=5","date":"2023-04-04","type":"pipeline","source":"Pharmaceutical Technology","summary":"Janssen launches once-daily option for prostate cancer drug Erleada - Pharmaceutical Technology","headline":"Janssen launches once-daily option for prostate cancer drug Erleada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOd2xjSVJFbGZxSjRmT2RmR2ZhS0llYXZBWEZaSlUydlhNejBzVzd3X0R3Yl9vRUZFOGpHYzdsUUkwd1BQS1hqbGk4YmJ3ZzNlY1ZnTEk0R1hJRnJ0XzBlcmQ4VDBtVHlUcE9DR0dVY1VkYmxldk1jTWplN0xHcTRBcVZyNHo1LXVIcnlyOHg2T05Ba2ppT18xNk5RcXBKZVFOR19ZLW1mMGxzZnhiQ2pNQUppdVhfT1NEdG5mcy05Zm1MQQ?oc=5","date":"2022-11-14","type":"pipeline","source":"Fierce Pharma","summary":"Johnson & Johnson 'Save Legs. Change Lives.' campaign brings PAD amputation awareness to Black community - Fierce Pharma","headline":"Johnson & Johnson 'Save Legs. Change Lives.' campaign brings PAD amputation awareness to Black community","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxNbnNEa2hfRU5XWXVSSTFPcGZWd3FBWjZrQW5CV3RsODVKNXdPSHN0S3FuWldPYmJrWTM0RDY1ZWwyeV9WZ2dEZEIwNWJYRnVOMWhJTXA0ZWlWTEF0SklmSHBrVVhyTDlrQTdtS2hSWmdFLURSNkF6bDZnVGQ0b3VaQ0trcjZ5NW9ZLWo5NTNRcXVKUzlMdXF2ekRmSFd3N2tTNGJ0WUNFQk5leVdiNllwdzVPVC1hdWpvejBTOGY1NmZZTWRhUm5SWG1hYVJaVUtOcERzYmxpR0tHTVI5aHRsSWtQSVlNYVZPazNBM1ZBLUc0THJzSFNfelpUeDBVcENBcm9Bdg?oc=5","date":"2022-11-04","type":"pipeline","source":"prnewswire.com","summary":"Janssen's Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations - prnewswire.com","headline":"Janssen's Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputatio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOTHZZamZDZTl2Y0tIY2lQOVdsNTdGd0Y4MS1vQmZsS0hPd0VGcVVBVUpGbW5iNG9fZnhjQ1lDLUdzOXc2YmNHRXM4TnBGVGI4NWVDUDZ6ejlIZXVrNGFCcWs1bFhSMUxCcVY4T09Ra3Ffb0g0Qk5EeUI4WE9Nd250Vmh3UkdWb0RwR19rc19WenhMYXBCVDRCNXk4T0pidw?oc=5","date":"2022-05-30","type":"pipeline","source":"Fierce Pharma","summary":"Prostate Cancer: Janssen’s Commitment to Patients Begins with Science - Fierce Pharma","headline":"Prostate Cancer: Janssen’s Commitment to Patients Begins with Science","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE84anhtNEpBSnFPQ1liWVI2ZlZDWXhHbmJDWDRoaENGaWRkeHJkYi0ySFVCdWtXQWNhLVhMU2F2a3o2Z3EybTdONmxQTHNnWlgxcElHX08tbUtFMDFYbG5J?oc=5","date":"2022-02-28","type":"trial","source":"Nature","summary":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial - Nature","headline":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQYzc1MkJxVjdlaF9TVDdGQU1XYTZfVlVFVm1vdkFraUdjU3J6WXVGVWdUazNLY3FLMkJfMUY3STRXOGlNS0RWVGNrRzFqU3JMdVBtby1wTWdsd2R3MjdDR1ZpMU92SXM3NTBEZU0tN1A0dE5pME1oS242dVJEUWN6X2ZuWHp1NndJVzRTeVJxS1dhcGtiNE82dWxTOThzMnRjc3ZtYlZlWVBMbGR3SGE1QVRycS1UbDQzUVlTMlM1SVJxQ19qS0N0QXRBUnp6M25UYjkzZVhPNE1rQVVTdVo2TFpGX2E3VkFEeF9jWHg3QlV3Zk9LeDFCOEo2M2lYVGV3dTd1cml0dTQ2N1BBOFIyX3gyT2k3aGZRU2lod0FsdFM0RDVabm50OHdIRmZ6YXpmbldBT0dubXNRb1VpcWc0?oc=5","date":"2021-10-25","type":"pipeline","source":"BioSpace","summary":"New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn's Disease and Ulcerative Colitis - B","headline":"New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patien","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOYUNuUXp6STVkWlc0b0RkSHAtQVg3ZUI1TzVIaHEyZ0tQbW1TZnRmbFl3TnNTejFWUUhGOVhzdk4wb1FDbUdkWlVEbDFaZlpHUXBqemViTEtpYVBiMjQ0WU9NY1hiamI5WU81ZmNZN25HUGl0U0cwNmhHSFY4dms0WXNacWY0MHRqUnZPWmdQakxkZnZpcUE0VWYwaWh5TUsxVkpKYzZfU1ZvOHNfeF83Q2ZNSjVtbWNyaEdKZVY4MkZuSGg2aWJVamRiTE00Zkxsd1U4dFhfbzhQeTg0X2dIRGRxM2FMTV8tQm1yY3BNdzcyaUVDRGhoQWdsb2lsZmxVSTBMVG9yUEtkc25VNWlhZnBhQTZSS2ZMRmJQNVh4aUM?oc=5","date":"2020-11-05","type":"trial","source":"prnewswire.com","summary":"Janssen Highlights Data from Rheumatology Portfolio During the American College of Rheumatology Convergence 2020 Virtual Scientific Program - prnewswire.com","headline":"Janssen Highlights Data from Rheumatology Portfolio During the American College of Rheumatology Convergence 2020 Virtual","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1qam14bHNEbFpvWVdQV0JCOXNSMWctZUVNN0hfam9sckdpQ3lteGhaR3BmLVJkV2s2ai10NGpTbG5nRmlkc3dHd1hWelNjZUVKbmdMNnZBejJhOXNZUlFWREduZzZaejVBUDR1RG9vTnJZdw?oc=5","date":"2020-02-25","type":"pipeline","source":"MultiVu","summary":"Johnson & Johnson Launches Heartline™ - MultiVu","headline":"Johnson & Johnson Launches Heartline™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQQVFRZzBTRUc2NTVlT3RDV3BPaS00X05oRWVxMzVFaTJaT3JHQzBINDVPa2RncjBVLUVyN1Z1dEs4SV94bHQyTF9KdUlxWlphMHFzS0NNcnZEVWNsVEJhMG5SZ01VdW84eHNhdzVWaGRvTHZwQXAwWjFLcEZHSFR6VlJvV1FfMk9IeWxGOW5leVJzcmxTa1M5TGw0M3dFUzlYM2dISzVuWExJbDduNFZXWTZhSVN0M2h4Zjh6U2JZNUVYZktVMXZz?oc=5","date":"2019-11-16","type":"trial","source":"prnewswire.com","summary":"Janssen Leverages Wearable Technology to Reimagine Clinical Trial Design - prnewswire.com","headline":"Janssen Leverages Wearable Technology to Reimagine Clinical Trial Design","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":4,"marketed":6,"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}